topic

662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Rohit Jain, Yuanquan Yang, Juskaran Chadha, Monica Chatwal, Sarah Raymond, Erika Saunders, Trey Poehlman, Wenyi Fan, Youngchul Kim, Jasreman Dhillon, Amir Mortazavi, Jingsong Zhang, Guru P Sonpavde

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A754; DOI: 10.1136/jitc-2023-SITC2023.0662
665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress
Mark N Stein, Jessica Hawley, Matthew Zibelman, Russell Pachynski, Robert Dreicer, Kevin Kayvan Zarrabi, Brian Miles, Ralph J Hauke, Margaret A Marshall, Bethan Jones, Vicky Wheeler, Sarah Sebastian, Katie Anderson, Antonella Vardeu, Charlotte Davis, Jennifer Bendall, Neal Shore

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A755; DOI: 10.1136/jitc-2023-SITC2023.0665
666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients
Timothy Yap, Ulka N Vaishampayan, Deepak Kilari, Randy Sweis, Minal Barve, Justin Gainor, Ahmad A Tarhini, Raghad Karim, Amna Sher, David Park, Sunil Babu, Rana McKay, Yawen Ju, Lan Liu, Susan Henry, Lu Gan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A756; DOI: 10.1136/jitc-2023-SITC2023.0666
667 Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab
Paula A Bousquet, Kaja CG Berg, Milena Blaga, Berit Nicolaisen, Roberto Oliveri, Mikkel Pedersen, Karoline Schjetne

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A757; DOI: 10.1136/jitc-2023-SITC2023.0667
669 Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer
Stephanie Gaillard, Manish Sharma, Daniel Vaena, Oladapo Yeku, Drew Rasco, Ecaterina Dumbrava, Kyriakos P Papadopoulos, Amita Patnaik, Ryan Sullivan, Benjamin Izar, Pierre Ferre, Eran Ophir, Inbal Barbiro, Gady Cojocaru, Adeboye H Adewoye, John Moroney

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A758; DOI: 10.1136/jitc-2023-SITC2023.0669
670 Development of a robust manufacturing process for AB-1015, an integrated circuit T cell (ICT) products, using targeted, CRISPR integration of transgenes by electroporation (CITE) editing
Ines Mende, Ben Tran, Kartoa Chow, Mark Kennedy, Monica Kukreja, Jenessa B Smith, Haixia Wang, Zain Dibian, Elisa Ha, Tejon McRae, Tanya Nguyen, Tommy Saephan, Erin Clagett, Nathan Lang, Raymond Lim, Jason Wu, Alice Chang, Liselle Guiang, Nadija Guner, Swetha Gunturu, Elizabeth Huang, Aditya Lalchandani, Max Lee, Sophia Phillips, Stephen Chang, Eric Chu, Ryan Zapata, En-Hsiang Chang, Rory Dai, Fadi Kandarian, Hayden Ko, Anton Nguyen, Wendy Nie, Kathan Parikh, Lindsay Rios, Xiangle Sun, Stella Tran, Peter Holman, Tim Sirichoke

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A759; DOI: 10.1136/jitc-2023-SITC2023.0670
671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer
Janos L Tanyi, Mark H O’Hara, Elizabeth Hexner, Amy Marshall, Julie Jadlowsky, Matthew Ferrara, Olivia Farrelly, Adam Runkle, Anne Chew, Emily Dowd, Vanessa Gonzalez, Joseph A Fraietta, Gabriela Plesa, Neil C Sheppard, Carl H June

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A760-A761; DOI: 10.1136/jitc-2023-SITC2023.0671
672 Induction of specific T-cell responses to tumor associated antigens and induction of B-cell responses in ovarian cancer patients by intradermal injection of vididencel
Annege Vledder, Hester Van Zeeburg, Satwinder Singh, Jeroen Rovers, Marco de Bruyn, Hans Nijman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A762; DOI: 10.1136/jitc-2023-SITC2023.0672
673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
Julie E Bauman, Vijay Kasturi, Martin Birkhofer, Robert Haddad

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A763; DOI: 10.1136/jitc-2023-SITC2023.0673
674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
Christine H Chung, Douglas Adkins, A Dimitrios Colevas, Cristina Rodriguez, Jong Chul Park, Michael K Gibson, Ammar Sukari, Barbara Burtness, Faye Johnson, Ricklie Julian, Nabil F Saba, Francis Worden, Lara A Dunn, Tanguy Y Seiwert, Robert M Jotte, Rami Haddad, Nashat Gabrail, Julie E Bauman, Marya Chaney, Laura Agensky, Apollina Goel, Steve Quayle, Steven Margossian, Matteo Levisetti, Sara Pai

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A764; DOI: 10.1136/jitc-2023-SITC2023.0674

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages